Nitric oxide delivery to cancer: why and how?
Hypoxia and blood flow heterogeneities are characteristics of solid tumours and are major obstacles for therapy. Exploiting the biology of nitric oxide (NO), a small radical with multiple functions, is particularly attractive to circumvent these sources of resistance and to sensitise tumour to cytotoxic treatments such as radiotherapy and chemotherapy. Indeed, while NO mediates angiogenic effects, NO may also promote tumour perfusion, drug delivery and oxygenation. Different strategies to deliver NO to tumours and pertaining to the FECS-EJC award laureate's work are reviewed, with a focus on their therapeutic potential. The development of techniques to monitor how and to which extent NO delivery influences the phenotype of a given tumour in a given patient is also discussed.
Sonveaux
Pierre
P
Unit of Pharmacology and Therapeutics, Université catholique de Louvain (UCL), Avenue E. Mounier 52, B-1200 Brussels, Belgium.
Jordan
Bénédicte F
BF
Gallez
Bernard
B
Feron
Olivier
O
D000818:Animals; D015687:Cell Hypoxia; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000628:therapy; D009389:Neovascularization, Pathologic; D009569:Nitric Oxide / Q000378:metabolism* / Q000494:pharmacology; D010100:Oxygen / Q000378:metabolism; D010477:Perfusion; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use; D012039:Regional Blood Flow; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use
D011838:Radiation-Sensitizing Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D010100:Oxygen